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ABSTRACT:
Deletion of ovarian carcinoma 2/disabled homolog 2 (DOC-2/DAB2) interacting 
protein (DAB2IP), is a tumor suppressor that serves as a scaffold protein involved in 
coordinately regulating cell proliferation, survival and apoptotic pathways. DAB2IP is 
epigenetically down-regulated in a variety of tumors through the action of the histone 
methyltransferase EZH2. Although DAB2IP is transcriptionally down-regulated in a 
variety of tumors, it remains unclear if other mechanisms contribute to functional 
inactivation of DAB2IP. Here we demonstrate that DAB2IP can be functionally 
down-regulated by two independent mechanisms. First, we identified that Akt1 can 
phosphorylate DAB2IP on S847, which regulates the interaction between DAB2IP and 
its effector molecules H-Ras and TRAF2. Second, we demonstrated that DAB2IP can be 
degraded in part through ubiquitin-proteasome pathway by SCFFbw7. DAB2IP harbors 
two Fbw7 phosho-degron motifs, which can be regulated by the kinase, CK1δ. Our data 
hence indicate that in addition to epigenetic down-regulation, two additional pathways 
can functional inactivate DAB2IP. Given that DAB2IP has previously been identified 
to possess direct causal role in tumorigenesis and metastasis, our data indicate that 
a variety of pathways may pass through DAB2IP to govern cancer development, and 
therefore highlight DAB2IP agonists as potential therapeutic approaches for future 
anti-cancer drug development.
INTRODUCTION
Tumor metastasis is a substantial setback 
encountered during clinical anti-cancer treatments, leading 
to increased mortality in cancer patients [1]. It has been 
well established that for many types of human cancers, 
tumor cells acquire the capability to metastasize to distant 
organs that ultimately result in organ failure and death 
[1, 2]. Therefore, elucidating the underlying molecular 
mechanisms that drive tumor growth and metastasis will 
provide further impetus for the development of more 
effective therapies, in part by eliminating metastatic 
cancer cells. Although the mechanisms remain largely 
unknown, overexpression of certain oncoproteins [3] 
or down-regulation of tumor suppressor proteins [4] 
have been demonstrated to play important roles in the 
process of tumor growth and metastasis. Deletion of 
ovarian carcinoma 2/disabled homolog 2 (DOC-2/
DAB2) interacting protein (DAB2IP), has been described 
as a tumor suppressor in various types of cancer [5-
9]. Furthermore, loss of DAB2IP expression during 
tumorigenesis is associated with poor prognosis and 
increased tumor metastasis [6, 8-11]. 
DAB2IP is often down-regulated by epigenetic 
modification in multiple aggressive cancers. In prostate 
cancer, DAB2IP expression was shown to be repressed by 
promoter methylation and histone modification, primarily 
through the action of the histone methyltransferase EZH2 
[12, 13], whereas in breast cancer [6], lung cancer [8], 
and gastrointestinal tumors [14], aberrant promoter 
hypermethylation was shown to down-regulate DAB2IP. 
Moreover, it was shown in prostate cancer that down-
regulation of DAB2IP expression results in resistance 
to ionizing radiation [15], which initiates epithelial-to-Oncotarget 3308 www.impactjournals.com/oncotarget
mesenchymal transition [11] and promotes tumor growth 
and metastasis [16]. Mechanistically, DAB2IP is involved 
in TNFα-induced apoptosis in prostate cancer cells by 
suppressing the ASK1-JNK and PI3K-Akt pathway [11], 
and in endothelial cells via the ASK1-JNK pathway [17].
DAB2IP, located at chromosome 9q33.1-q33.3, is 
a member of the Ras-GTPase activating protein family 
(RAS GAP) that inactivates Ras largely by promoting 
conversion of GTP into GDP [18]. Functionally, DAB2IP 
serves as a scaffold protein involved in coordinately 
regulating cell proliferation, survival and apoptotic 
pathways [19]. Through interaction with various factors, 
DAB2IP can modulate the activities of various pathways 
including Ras-Raf-ERK, ASK1-JNK, and PI3K-Akt, 
through which loss of DAB2IP can deregulate survival 
and apoptosis pathways, leading to tumor development. 
Specifically,  DAB2IP  inhibits  the  RAS  pathway  by 
directly binding to and inactivating H-Ras and R-Ras 
through its Ras GTPase activity [18], regulates the ASK1 
pathway by blocking interaction of ASK1 with its inhibitor 
14-3-3 [17], and binds to and inactivates the Akt kinase 
[19].
Prostate cancer is largely curable if diagnosed early 
in disease progression, however, there are no effective 
therapies for metastatic disease. Recent studies have 
identified DAB2IP as a regulator of metastatic prostate 
cancer, and is one of the few genes with a direct causal 
role in driving prostate cancer metastasis. DAB2IP has 
roles in both tumor initiation and metastasis, whereby 
DAB2IP controls primary tumor growth through activating 
Ras  and  drives  metastasis  through  controlling  NF-κB 
through regulation of TRAF2 [16]. Although DAB2IP 
is often epigenetically down regulated in a variety of 
cancers through EZH2 activation, we set out to determine 
if DAB2IP can also be functionally inactivated through 
signaling or degradation pathways. To this end, we have 
identified that DAB2IP is functionally inactivated by Akt-
mediated phosphorylation, controlling DAB2IP activity on 
both the Ras and TRAF2 downstream effector molecules. 
In addition, we have identified that DAB2IP protein levels 
can be controlled by Fbw7-mediated ubiquitination and 
subsequent degradation.
RESULTS
DAB2IP is phosphorylated by Akt1
Previous studies demonstrated that DAB2IP is 
epigenetically down regulated in many tumors through 
the action of EZH2 or promoter methylation [6, 8, 12-14]. 
We set out to determine if there are additional mechanisms 
functionally regulating DAB2IP. Scanning the DAB2IP 
protein  sequence,  we  identified  two  consensus  Akt 
sites (RxRxxpS/T) located in the carboxy terminus of 
DAB2IP at Serine-847 and Serine-907 (Figure 1A). To 
test if this consensus sequence could serve as a bona fide 
phosphorylation site in DAB2IP, we tested if any Akt 
or similar kinases (Akt1, Akt2, SGK and ribosomal S6 
kinase (S6K)) were able to phosphorylate DAB2IP. Using 
a phospho-Akt substrate specific antibody, we found that 
only Akt1 expression led to increased phosphorylation of 
Figure 1: DAB2IP is phosphorylated by Akt1. (A) 
Alignment of human, mouse, and rat DAB2IP sequences 
surrounding putative Akt substrate motif. (B) 293T cells 
transfected with FLAG-DAB2IP with vector alone, Akt1, 
Akt2, S6K, or SGK were immunoprecipitated with anti-
FLAG, and western blotted with antibodies against RxxpS/T, 
FLAG, HA, and Tubulin. (C) 293T cells transfected with wild-
type, S847A, S907A and S847A/S907A FLAG-DAB2IP were 
immunoprecipitated with anti-FLAG, and western blotted with 
antibodies against RxxpS/T, FLAG, and Viniculin.Oncotarget 3309 www.impactjournals.com/oncotarget
DAB2IP (Figure 1B). By mutating each phosphorylation 
site within the two consensus Akt motifs, we found that 
S847 was primarily phosphorylated by Akt1 (Figure 1C). 
These data indicate that Akt1 can phosphorylate DAB2IP 
in the carboxy terminus at S847.
Phosphorylated DAB2IP blocks interaction with 
H-Ras and TRAF2
Loss of DAB2IP was shown to trigger RAS, ERK 
and Akt activation [16], and interact with TRAF2 via its 
C-terminal domain [20]. Interestingly, our identified Akt1 
phosphorylation site lies in the C-terminus of the proline-
rich interaction domain in DAB2IP that is involved in 
binding TRAF2 and ASK1. To test if phosphorylation at 
S847 by Akt1 also influences the association of DAB2IP 
and TRAF2, we tested the interaction of phospho-mimetic 
(S847D) and non-phosphorylatable (S847A) mutants 
with TRAF2. Notably, we found that the DAB2IP S847A 
mutant bound more efficiently while the DAB2IP S847D 
mutant had reduced binding to TRAF2 (Figure 2A). 
Likewise, we found that the ability of DAB2IP to bind 
to Ras was also affected by the phosphorylation status 
of DAB2IP as the interaction between DAB2IP and Ras 
is regulated by the phosphorylation status at S847, with 
the non phosphorylation substitution (S847A) having 
increased interaction, while a phosphomimetic substitution 
(S847D) showing reduced binding (Figure 2B). These 
results indicate that the ability of the scaffold protein 
DAB2IP to interact with TRAF2 and Ras is controlled 
in part through Akt1-dependent phosphorylation in the 
C-terminus of DAB2IP.
In addition to TRAF2, DAB2IP has been shown to 
regulate the RAS-ERK signaling pathway, where depletion 
of DAB2IP leads to MAPK pathway activation (Figure 2C 
and [16, 19]). To test if phosphorylation at the Akt site 
of DAB2IP is important for its ability to control MAPK 
pathway activation, we assessed the MAPK activation in 
PC3 cells, which have limited expression of DAB2IP. We 
found that expression of wild-type DAB2IP resulted in 
lower MAPK activation as measured by phosphorylation 
of ERK (Figure 2D). Expression of the phospho-mimetic 
mutant (S847D) of DAB2IP resulted in an increase in 
MAPK activation (Figure 2D). Induced MAPK activity 
that we observed with phosphorylation at S847D was 
Figure 2: Phosphorylation at S847 controls DAB2IP function. (A) 293T cells transfected HA-H-Ras with vector alone, wild-type 
and S847A and S847D FLAG-DAB2IP were immunoprecipitated with anti-HA, and western blotted with antibodies against FLAG and 
HA. (B) 293T cells transfected Myc-TRAF2 with vector alone, wild-type and S847A and S847D FLAG-DAB2IP were immunoprecipitated 
with anti-Myc, and western blotted with antibodies against FLAG and Myc. (C) PC3 cells transduced with lentivirus expressing GFP, wild-
type, S847D or R289L HA-DAB2IP were western blotted with antibodies against DAB2IP, pERK, total ERK, and Tubulin. (D) HeLa cells 
were infected with virus expressing shRNA against GFP or DAB2IP. Following selection of infected cells, lysates were western blotted with 
antibodies against DAB2IP, pERK, total ERK, Akt pS475, total Akt, and Vinculin. Oncotarget 3310 www.impactjournals.com/oncotarget
similar to what was observed for a catalytically inactive 
RasGAP mutant of DAB2IP (R289L), suggesting that 
the regulation of DAB2IP binding to Ras was important 
for DAB2IP to control MAPK activity. Therefore, our 
results indicate that phosphorylation at S847 of DAB2IP 
is important for its downstream effector functions, and 
thus regulation of the phosphorylation status at S847 is 
important for the tumor suppressor roles of DAB2IP. 
DAB2IP interacts with Cullin-Ring E3 ligases
Given that DAB2IP is a potent tumor suppressor, 
and is down-regulated in a variety of human tumors, we 
intend to determine if DAB2IP is actively regulated by 
proteasome-mediated degradation in addition to being 
functionally regulated by phosphorylation. To this end, 
the ubiquitin proteasome system (UPS) plays an important 
role in the timely regulation of key cellular proteins and 
thereby controlling many cellular processes including cell 
signaling and cell cycle regulation [21]. Dysfunction of 
the UPS is involved in the development of many diseases 
including cancer [22, 23]. 
It is well established that Cullin-Ring complexes are 
the largest family of E3 ligases. Therefore, we determined 
whether a specific Cullin-Ring E3 ligase interacts with 
DAB2IP. We found that DAB2IP interacted with Cullin-1 
and Cullin-4A, while it did not interact with Cullin-2, 
Cullin-3, or Cullin-5 (Figure 3A). Cullin-1 based E3 
ligases are the most well studied Cullin-Ring complexes, 
and are named SCF complexes due to the presence of 
the components Skp1, Cullin-1 and an associated F-box 
protein that directs substrate recognition. Consistent with 
an interaction between Cullin-1 and DAB2IP, we found 
that DAB2IP interacted with Rbx1 and Skp1, common 
complex component of Cullin-1 based SCF complexes 
Figure 3: DAB2IP stability is controlled by Cullin-Ring mediated degradation. (A) 293T cells transfected FLAG-DAB2IP 
with vector alone, or Myc-tagged Cullin 1-5 were immunoprecipitated with anti-FLAG or anti-Myc, and western blotted with antibodies 
against FLAG and Myc. (B) 293T cells transfected FLAG-DAB2IP with vector alone or Myc-Rbx1 were immunoprecipitated with anti-
FLAG or anti-Myc, and western blotted with antibodies against FLAG and Myc. (C) 293T cells transfected FLAG-DAB2IP with vector 
alone, or Myc-Skp1 were immunoprecipitated with anti-FLAG or anti-Myc, and western blotted with antibodies against FLAG and Myc. 
(D) DU145 cells were infected with virus expressing shRNA against GFP or 2 independent shRNAs to Cullin 1. Following selection of 
infected cells, lysates were western blotted with antibodies against DAB2IP, Cullin 1, and Tubulin.Oncotarget 3311 www.impactjournals.com/oncotarget
(Figure 3B and 3C). Furthermore, depletion of cells with 
Cullin-1 shRNA resulted in an increase in DAB2IP protein 
abundance (Figure 3D). 
SCFFbw7 regulates DAB2IP stability
The human genome harbors 69 F-Box proteins, 
where β-TRCP and Fbw7 are the most well-established 
substrate recognition components of the SCF complex, 
and dysregulation of these F-box proteins can contribute 
to cancer development [24-26]. Scanning the DAB2IP 
protein sequence, we identified two potential phospho-
degron sequences (S15 and S578) that share partial 
homology to the consensus Fbw7 substrate recognition 
motif (Figure 4A). We found that Fbw7 interacted with 
DAB2IP (Figure 4B), indicating a role for Fbw7 as the 
F-Box protein involved in recruiting DAB2IP to the 
SCF complex. Fbw7 is frequently mutated in T-ALL, 
and plays a critical role in T-ALL cancer development 
[27], where common mutations in Fbw7 found in T-ALL 
abrogate interaction between Fbw7 and substrate proteins. 
Consistent with DAB2IP being a substrate of Fbw7, we 
found that three T-ALL associated mutations in Fbw7 
(R465H, R479L, and R505C) no longer interacted of Fbw7 
with DAB2IP (Figure 4B), providing further evidence that 
DAB2IP interaction with Fbw7 is through the substrate 
recognition domain of Fbw7. We next tested if mutation 
of the Fbw7 phospho-degron motifs in DAB2IP resulted 
in loss of biding between these two factors. Mutation of 
Serine-15 and Serine 578 in DAB2IP resulted in loss of 
binding between DAB2IP and Fbw7 (Figure 4C). These 
results combined suggest that the substrate recognition 
F-Box motif in Fbw7 binds to the Fbw7 phospho-degron 
motif in DAB2IP.
With DAB2IP interacting with SCFFbw7, we wanted 
to next determine if this Cullin-Ring E3 ligase controls the 
stability of DAB2IP. To test this, we depleted Fbw7 and 
Figure 4: Fbw7 interacts with and regulates DAB2IP stability. (A) Alignment of human, mouse, and rat DAB2IP sequences 
surrounding putative Fbw7 degron motif. (B) 293T cells transfected with FLAG-DAB2IP and vector alone, wild-type, R465H, R479L, or 
R505C HA-Fbw7 were immunoprecipitated with either anti-FLAG or anti-HA, and western blotted with antibodies against FLAG and HA. 
(C) 293T cells transfected HA-Fbw7 with vector alone, wild-type or S15/578A FLAG-DAB2IP were immunoprecipitated with anti-FLAG, 
and western blotted with antibodies against FLAG and HA. (D) T98G cells were infected with virus expressing shRNA against GFP or 
Fbw7. Following selection of infected cells, lysates were western blotted with antibodies against DAB2IP, Fbw7, Cyclin E, and Vinculin. 
(E) Wild-type and Fbw7 knockout HCT116 cells were western blotted with antibodies against DAB2IP, Fbw7, Cyclin E, and Tubulin.Oncotarget 3312 www.impactjournals.com/oncotarget
assessed protein abundance of DAB2IP. We observed that 
knockdown of Fbw7 resulted in an increase in DAB2IP 
protein (Figure 4D). Additionally, deletion of Fbw7 in 
HCT116 cells also led to an increase in DAB2IP protein 
abundance (Figure 4E). Our results indicate that Fbw7 
promotes the degradation of DAB2IP through recruitment 
to SCFFbw7 complex for degradation.
Phosphorylation-dependent interaction and 
degradation of DAB2IP
Fbw7-mediated degradation often depends on 
the presence of a phospho-degron motif in the target 
protein. Mutation of both of these serine residues led to a 
decrease in binding between Fbw7 and DAB2IP (Figure 
4C), indicating that one, or both, of these motifs are 
important for interaction between DAB2IP and Fbw7. 
To determine which kinase is involved in the regulation 
of phosphorylation within DAB2IP degron motifs, we 
tested whether CK1α/β, CK1δ, GSK3, or ERK1 could 
alter protein abundance of DAB2IP. We found that 
overexpression of CK1δ led to a decrease in DAB2IP 
(Figure 5A). Furthermore, depletion of CK1δ resulted in 
an increase in DAB2IP protein abundance (Figure 5B). 
Our data is consistent with the notion that degradation of 
DAB2IP by SCFFbw7 requires phosphorylation within the 
degron motif in DAB2IP, which is possibly carried out by 
CK1δ. 
DISCUSSION
DAB2IP is an emerging tumor suppressor, which 
is often epigenetically down-regulated in cancer. Given 
a direct causal role of DAB2IP for regulating cancer 
metastasis, we hypothesize that DAB2IP could be 
targeted for functional inactivation through additional 
posttranslational  mechanisms.  Here  we  identified  two 
independent pathways that can negatively regulate 
DAB2IP function; inactivation through Akt mediated 
phosphorylation and degradation through SCFFbw7-
mediated ubiquitination and degradation.
Although DAB2IP is often epigenetically down 
regulated by EZH2 activation in many tumors, we defined 
a novel pathway of functionally inactivating DAB2IP in 
prostate cancer cells through Akt activity. We identified 
an Akt consensus sequence in DAB2IP, and demonstrated 
that this site is a possible target of Akt. Furthermore, 
we have found that phosphorylation of this site directly 
affects DAB2IP association with Ras and TRAF proteins, 
implicating  this  modification  in  controlling  DAB2IP 
regulation of downstream effector pathways. This is of 
particular interest as Akt is negatively regulated by PTEN, 
suggesting that the loss of PTEN in prostate cancer could 
possibly inactivate DAB2IP through Akt activation, 
thereby perhaps leading to greater prevalence of prostate 
cancer metastasis (Figure 5C)
Recent results have shown that DAB2IP can 
suppress the Akt pathway through direct interaction. 
Our results suggest that, in addition to Akt inactivating 
DAB2IP, DAB2IP can control of Akt can lead to a positive 
feedback loop. Where increased Akt activity will further 
induce itself through negative regulation of DAB2IP. This 
feedback loop therefore leads to even greater Akt activity 
in cell, which are also primed to undergo metastasis 
Figure  5:  CK1δ  regulates  phosphorylation  of  the 
DAB2IP degron motif. (A) 293T cells transfected with GFP, 
FLAG-DAB2IP and HA-Fbw7 with vector alone, CK1δ, CK2 
(α and β), GSK3, or ERK1 were western blotted with antibodies 
against FLAG, GFP, and Tubulin. (B) 293T cells were infected 
with virus expressing shRNA against GFP or CK1δ. Following 
selection of infected cells, lysates were western blotted with 
antibodies against DAB2IP, CK1δ, and Tubulin. (C) Schematic 
depicting regulation of DAB2IP by Akt and Fbw7 pathways.Oncotarget 3313 www.impactjournals.com/oncotarget
through additional downstream pathways dysregulated 
with inhibition of DAB2IP. Therefore, targeting this 
feedback loop through increasing DAB2IP protein 
abundance or function could be a unique therapeutic 
possibility. 
In addition to functional inactivation of DAB2IP 
by Akt, we identified that DAB2IP is also targeted for 
proteasome-mediated degradation driven by the SCFFbw7 
E3 ubiquitin ligase. To this end, we have identified that the 
SCFFbw7 E3 ubiquitin ligase interacts with, and promotes 
the degradation of, DAB2IP. Furthermore, we have 
identified a phospho-degron motif within DAB2IP that is 
commonly utilized by Fbw7 for substrate recruitment to 
the SCF complex. We have identified CK1δ as a potential 
upstream modifying kinase regulating the phosphorylation 
of this Fbw7 phospho-degron motif within DAB2IP. 
Overexpression and knockdown of CK1δ leads to the 
loss and stabilization of DAB2IP, respectively, suggesting 
a direct role for CK1δ in mediating the degradation of 
DAB2IP by Fbw7. Identifying key pathways regulating 
degradation of DAB2IP could prove to be a potential 
therapeutic target by restoring DAB2IP protein abundance 
through inhibition of its degradation.
Recent studies have indicated that DAB2IP down-
regulation has implications in resistance to ionizing 
radiation [15], initiation of the epithelial-to-mesenchymal 
transition [11] and promotes tumor growth and metastasis 
[16]. Here, by identifying that the protein stability of 
DAB2IP is regulated by the SCFFbw7 E3 ubiquitin ligase, 
suggests that utilizing inhibitors of this E3 ligase complex 
could serve as a mechanism to block these processes by 
protecting DAB2IP protein levels in cellular contexts 
where DAB2IP expression is suppressed.
Interestingly, Fbw7 is often referred to as a tumor 
suppressor for its roles in regulating the degradation of 
potent oncogenes such as Cyclin E, c-Myc, c-Jun, Mcl-
1, mTOR and Notch-1 [28]. Here we find that Fbw7 
is involved in the degradation of a tumor suppressor. 
However, this has also recently been the case for another 
RasGAP molecules, neurofibromin (or NF1), which is 
also a known tumor suppressor [29]. The role of FBW7 
regulating two known tumor suppressors, both of which 
are RasGAPs, for degradation, suggest a potential unifying 
role of DAB2IP and NF1 being under the control of Fbw7-
mediated degradation which requires further studies of 
these pathways and their stability control by Fbw7 to 
elucidate the implications in cancer development and 
progression.
Given a causal role for DAB2IP in driving 
progression of prostate cancer towards metastasis, and 
the prevalence of PTEN loss early in prostate cancer 
development, understanding how DAB2IP is regulated 
is of critical importance. In summary, our results identify 
two new pathways leading to the functional inactivation 
of the tumor suppressor DAB2IP through Akt-mediated 
phosphorylation and SCFFbw7-mediated degradation. Our 
work further suggest that in part by restoring DAB2IP 
expression to suppress cancer cell growth, proliferation 
and metastasis, Akt inhibitors or Fbw7/CKI inhibitors may 
be beneficial in treating various types of human cancers, 
particularly the metastatic cancers that are associated with 
poor survival rates.
MATERIALS AND METHODS
Cell Culture
HeLa, 293T, HCT116, and T98G cells were cultured 
in DMEM medium (Life Technologies, CA) supplemented 
with 10% FBS, penicillin and streptomycin. The cell lines 
DU145 and PC3 were cultured in RPMI 1640 medium 
with 10% FBS and antibiotics.
Plasmids
Myc-Cullin 1, Myc-Cullin 2, Myc-Cullin 3, Myc-
Cullin 4A, and Myc-Cullin 5 constructs were kind gifts 
from J. DeCaprio (Dana-Farber Cancer Institute, Boston, 
MA). HA-Fbw7 was a kind gift form Dr. Keiichi I 
Nakayama (Kyushu University, Fukuoka, Japan). ERK1 
plasmid was a kind gift from Dr. John Blenis (Harvard 
Medical School, Boston, MA). HA-Ras plasmid was a 
kind gift from Dr. Lewis Cantly (Weill Cornell Medical 
College, New York, NY). shRNA CK1δ was a kind gift 
from Dr. William Hahn (Dana-Farber Cancer Institute). 
Myc-TRAF2, CK1δ, CK1α and CK1βδ where kind gifts 
from Dr. Wade Harper (Harvard Medical School). The 
following plasmids were previously described: Akt1, Akt2 
and S6K [30]; SGK [31]; Myc-Rbx1, Myc-Skp1, GSK3, 
shRNA Cullin-1 and shRNA Fbw7 [32]; FLAG-DAB2IP 
and shRNA DAB2IP [16]. 
Cell transfection and viral transduction procedures
For cell transfection, 5×105 HeLa or 293T cells 
were seeded in 100-mm plates and transfected using 
Lipofectamine (Invitrogen) in OptiMEM medium 
(Invitrogen) for 48 hours according to the manufacturer’s 
instructions. For viral transduction experiments, 6×105 
HEK 293T cells were seeded in 60-mm dishes and 
cotransfected the next day with each lentivirus or 
retrovirus vector, along with helper plasmids (i.e., gag-
pol and VSV-G were used for lentiviral infections). Media 
with progeny virus from transfected cells was collected 
every 24 h for 2 d, and then filtered with 0.45-μm filters 
(Millipore). After infection, the cells were selected with 
1  μg/ml  puromycin  (Sigma-Aldrich)  for  72  hours  to 
eliminate the uninfected cells before collecting the whole 
cell lysates (WCLs) for the subsequent biochemical 
assays. Knockdown or overexpression in the transduced 
cells was confirmed by western blot analysis.Oncotarget 3314 www.impactjournals.com/oncotarget
Antibodies and Reagents
The following antibodies were used for this study. 
RxxpS/T (9614), pERK (4370), ERK (4905), pS473-Akt 
(4501), Akt (4691) and Anti-Cullin 1 (4995) were from 
Cell Signaling Technology. Cyclin E (Sc-247), c-Myc 
9E10 (sc-40), and HA Y-11 (sc-805) were from Santa 
Cruz Biotechnology. Fbw7 (A301-720A) was from Bethyl 
Laboratories.  α-Tubulin  (T-5168),  Vinculin  (V-4505), 
polyclonal FLAG (F-2425), monoclonal FLAG (F-3165), 
HA agarose beads (A-2095), peroxidase-conjugated 
α-mouse secondary antibody (A-4416) and peroxidase-
conjugated α-rabbit secondary antibody (A-4914) were 
from Sigma. GFP (632380) was from Invitrogen. DAB2IP 
antibody was previously described [16].
Immunoprecipitation and Western Blotting
Cells were lysed in EBC-lysis buffer (50 mM Tris, 
pH 8.0, 120 mM NaCl, and 0.5% NP-40) supplemented 
with protease inhibitors (Complete Mini; Roche) and 
phosphatase inhibitors (phosphatase inhibitor cocktail set I 
and II; EMD Millipore). The protein concentrations of the 
lysates were measured using a protein assay reagent (Bio-
Rad Laboratories, CA) on a DU-800 spectrophotometer 
(Beckman Coulter). The lysate samples were then resolved 
by SDS-PAGE and immunoblotted with the indicated 
antibodies. For immunoprecipitation assays, 20 hrs of 
post transfection, cells were treated with 10 μM MG132 
overnight before harvesting for immunoprecipitation. 1 
mg of protein lysates were incubated with the appropriate 
antibodies (1-2 μg) overnight at 4˚C, followed by addition 
of carrier beads. Immunocomplexes were washed five 
times with NETN buffer (20 mM Tris, pH 8.0, 100 mM 
NaCl, 1 mM EDTA, and 0.5% NP-40) before being 
resolved by SDS-PAGE and immunoblotted with indicated 
antibodies.
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